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Objectives. Our aim was to design and evaluate a new and easily
administered recombinant tissue-type plasminogen activator (rt-
PA) regimen for thrombolysis in acute myocardial infarction
(AMI) based on established pharmacokinetic data that improve
the reperfusion success rate.
Background. Rapid restoration of Thrombolysis in Myocardial
Infarction (TIMI) grade 3 flow is a primary predictor of mortality
after thrombolysis in AMI. However, TIMI grade 3 patency rates
90 min into thrombolysis of only 50% to 60% indicate an obvious
need for improved thrombolytic regimens.
Methods. Pharmacokinetic simulations were performed to de-
sign a new rt-PA regimen. We aimed for a plateau tissue-type
plasminogen activator (t-PA) plasma level similar to that of the
first plateau of the Neuhaus regimen. These aims were achieved
with a 20-mg rt-PA intravenous (i.v.) bolus followed by an 80-mg
i.v. infusion over 60 min (regimen A). This regimen was tested in
a consecutive comparative trial in 80 patients versus 2.25 106 IU
of streptokinase/60 min (B), and 70 mg (C) or 100 mg (D) of rt-PA
over 90 min. Subsequently, a confirmation trial of regimen A in
254 consecutive patients was performed with angiographic assess-
ment by independent investigators of patency at 90 min.
Results. The comparative phase of the trial yielded, respec-
tively, TIMI grade 3 and total patency (TIMI grades 2 and 3) of
80% and 85% (regimen A), 35% and 50% (B), 50% and 55% (C)
and 60% and 70% (D). In the confirmation phase of the trial,
regimen A yielded 81.1% TIMI grade 3 and 87.0% total patency. At
follow-up angiography 7 (4.1%) of 169 vessels had reoccluded.
In-hospital mortality rate was 1.2%. Nadir levels of fibrinogen,
plasminogen and alpha2-antiplasmin were 3.6 6 0.8 mg/ml, 60 6
21% and 42 6 16%, respectively (mean 6 SD). Fifty-seven patients
(22.4%) suffered from bleeding; 3.5% needed blood transfusions.
Conclusions. The 60-min alteplase thrombolysis in AMI proto-
col achieved a TIMI grade 3 patency rate of 81.1% at 90 min with
no indication of an increased bleeding hazard; it was associated
with a 1.2% overall mortality rate. These results are substantially
better than those reported from all currently utilized regimens.
Head to head comparison with established thrombolytic regimens
in a large-scale randomized trial is warranted.
(J Am Coll Cardiol 1997;30:1611–7)
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In the past two decades, thrombolysis has become the mainstay
in the treatment of acute myocardial infarction (AMI) (1–3).
However, recent trials indicate that only Thrombolysis in
Myocardial Infarction (TIMI) grade 3, and not TIMI grade 2
coronary blood flow, if achieved early, substantially lessens
infarct mortality (4–6). Thrombolytic therapy today is limited
by the fact that even the most aggressive recombinant tissue-
type plasminogen activator (rt-PA) regimens achieve coronary
reperfusion at 90 min in only slightly .50% of patients (5).
This fact has prompted an intense search for improved throm-
bolytic protocols, which include rt-PA (7) and its newer
derivatives (8–10), as well as conjunctive therapy with direct
inhibitors of thrombin activation or platelet aggregation
(11,12). Though seemingly very successful in a small single-
center pilot trial in 84 patients (7), a double-bolus rt-PA
regimen did not result in increased TIMI grade 3 patency rates
at 90 min in a larger scale randomized angiographic trial (13)
and failed to fulfill expectations in a large cohort of patients
with infarction (14). With 40% to 50% of infarct vessels
remaining insufficiently reperfused, the need for better throm-
bolytic regimens persists. We report here a new accelerated
rt-PA regimen, the 60-min alteplase protocol, that achieved
TIMI grade 3 coronary blood flow in the infarct-related vessel
in 80% of patients. We initially performed a small comparative
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phase of the trial with routinely used thrombolytic regimens.
We subsequently performed a large confirmation phase of the
trial in 254 consecutive patients with AMI, which corroborated
our results. These favorable results were achieved without an
increased risk of hemorrhage or stroke.
Methods
Study design. This study in consecutive patients with AMI
consisted of two parts. The first part was an open label,
nonrandomized, prospective, angiographically controlled
comparison with three standard regimens. The second part
was an open, prospective angiographically controlled dose-
confirmation study in consecutive patients. On enrollment in
the study, all patients were given 250 mg of oral aspirin and
5,000 IU of heparin as an intravenous (i.v.) bolus, followed by
an i.v. infusion of 1,000 IU/h (starting dose) that was intended
to maintain an activated partial thromboplastin time target
range between 50 and 80 s and was not interrupted during
thrombolysis. Heparin infusion was continued during the first 3
days of therapy.
During the first comparison phase of the study, thrombol-
ysis was performed with one of the following four predefined
thrombolytic regimens. Regimen A was derived from the rt-PA
pharmacokinetic simulations as outlined later. Regimen B was
a continuous infusion of 2.25 MU of streptokinase over 60 min.
Regimen C was 10 mg of rt-PA given as an i.v. bolus followed
immediately by 50 mg infused i.v. over 60 min and a further
10 mg infused over the next 30 min. This regimen was also used
by the investigators of the European Cooperative Study Group
(15,16). Regimen D was 15 mg of rt-PA given as an i.v. bolus
followed immediately by 50 mg infused i.v. over 30 min and a
further 35 mg infused over the next 60 min as described by
Neuhaus et al. (17,18). During the second confirmation phase
of the study, the newly designed rt-PA dose regimen (A) was
given to all consecutive patients.
The first coronary angiogram was recorded at 90 min after
the start of therapy. If the infarct-related coronary artery was
still occluded (TIMI grade 0 to grade 2 flow) it was left to the
discretion of the investigator to perform rescue percutaneous
transluminous coronary angioplasty (PTCA). On day 3, hepa-
rin infusions were stopped and patients were given 10,000 IU
of subcutaneous heparin twice daily. The maintenance dose of
aspirin was 100 to 250 mg once daily. All other medication—
including antiarrhythmic drugs, diuretic agents, opiate analge-
sics or sedatives—was given as clinically required. To avoid
interference with any of the additionally given drugs, the
thrombolytic agents were given through a separate intravenous
line. If the first angiogram revealed TIMI grade 3 flow, the
investigators were requested to perform follow-up angiography
before the patient’s discharge. The study protocol was ap-
proved by the local ethics committee.
Patient selection. Patients of either gender, with symptoms
characteristic of AMI occurring ,6 h before therapy and not
responsive to a single dose of sublingual nitrates or nifedipine,
were considered for study entry if they met the following
electrocardiographic (ECG) criteria: ST segment elevation 1)
.0.2 mV in leads I to aVF or V5 and V6, or 2) .0.3 mV in
leads V1 through V4, or 3) .0.1 mV in leads III and aVF plus
corresponding ST segment depression .0.2 mV in leads V1
and V2. More stringent ECG criteria were applied in this
cohort of patients to avoid enrollment of patients whose ECG
changes originated from other cardiac diseases. Exclusion
criteria were defined as follows: 1) history of recent cerebro-
vascular accident, 2) active or recent gastric ulcer, 3) overt
bleeding, 4) recent major surgery or trauma, 5) known bleed-
ing tendency or coumarin therapy, 6) known renal or hepatic
failure, 7) childbearing potential, 8) end-stage malignancies, 9)
all other contraindications to either thrombolytic therapy,
heparin therapy or cardiac catheterization, and 10) inability to
give informed consent. A history of remote AMI was not
considered an exclusion criterion if the infarction occurred in
a region clearly distinct from the current occlusion site.
Patients with left bundle branch block were not entered into
this study because of possible difficulties in definition of the
localization of the acutely infarcted region. If patients fulfilled
the entry criteria, informed consent was obtained before they
were enrolled into the study.
Assessment of angiograms. Cineangiograms were re-
corded on 16-mm cinefilm and assessed for perfusion in the
infarct-related coronary artery by two experienced, indepen-
dent investigators. These investigators did not know the dosage
regimen administered to each patient. In the event of discor-
dant patency judgments, a third independent investigator who
also did not know the dosage regimen was asked for final
judgment. Perfusion was assessed according to the score first
introduced by the TIMI investigators (19), with rating grade
0 5 no perfusion in the distal coronary bed; grade 1 5
penetration of the thrombus with minimal opacification be-
yond the occlusion; grade 2 5 partial perfusion with delayed
but complete opacification (.3 cycles) and delayed emptying
of the distal vessel; and grade 3 5 complete filling and
emptying of the vessel at a rate comparable to that of
nonseverely stenosed coronary arteries. On the basis of this
grading system, thrombolytic therapy was rated successful only
when perfusion was rated TIMI grade 3 flow at the first
injection of contrast medium into the infarct-related coronary
artery.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
AP 5 alpha2-antiplasmin
ECG 5 electrocardiographic
Fg 5 fibrinogen
i.v. 5 intravenous, intravenously
PLG 5 plasminogen
PTCA 5 percutaneous transluminal coronary angioplasty
rt-PA 5 recombinant tissue-type plasminogen activator
TIMI 5 Thrombolysis in Myocardial Infarction
t-PA 5 tissue-type plasminogen activator
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Pharmacokinetic simulations. Pharmacokinetic simula-
tions were performed with the program TopFit (20). The data
base for simulations comprised model parameters that were
derived from fitting of a three-compartment model to rt-PA
plasma antigen concentration-time profiles of 12 patients with
AMI who underwent rt-PA lysis (21). In that study, the
patients were administered the standard dosage regimen of
100 mg of rt-PA over 3 h, that is, an initial 10-mg bolus
followed by 50 mg infused over 1 h and 40 mg infused over the
next 2 h. Individual fits were performed for each patient data
set, and mean pharmacokinetic microconstants were calcu-
lated over all patients. Pharmacokinetic simulations were
performed on the basis of the following predefined require-
ments. A brief high peak concentration should be achieved by
an initial bolus (the simulated bolus duration was 2 min). To
avoid an increase in bleeding hazards, steady state rt-PA levels
during infusions should not exceed those that are generated
with the regimen of Neuhaus et al. (17,18) during its first
plateau. These levels, however, should be maintained for
60 min instead of only 30 min. Finally, the new regimen should
offer more simple and convenient handling properties than
those of the regimen of Neuhaus et al.
Assays for coagulation variables and tissue plasminogen
activator (t-PA). Citrated blood samples were collected (final
concentration 0.01 mmol) at baseline and at 120 min into
thrombolysis. From these samples plasminogen and alpha2
antiplasmin plasma levels were determined. From additional
citrated blood samples containing aprotinin (final concentra-
tion 200 KIU/ml) fibrinogen levels were assessed. After collec-
tion, the blood samples were immediately transferred to the
hematology laboratory where they were centrifuged at 3,000 g.
The resulting plasma samples were frozen within 2 h and
stored at 280°C until analysis.
For fibrinogen determinations, the Clauss method (22) was
employed. Plasminogen and alpha2-antiplasmin determina-
tions used the chromogenic peptide substrate H-D-Val-Leu-
Lys-pNA (S-2251) according to the method of Friberger et al.
(23). To confirm the predicted plasma levels, aliquots of the
citrated plasma from 12 randomly selected patients were
diluted 1:100 or 1:1 with a 0.9% NaCl dilution buffer contain-
ing 1% albumin, 0.5% Tween 20, and 0.5 mmol/liter EDTA.
The samples were assayed for t-PA–antigen plasma levels
according to the method described by Wojta et al. (24) at
baseline (undiluted) and at 30 and 60 min (diluted 1:100) and
at 120 min (diluted 1:1) after thrombolysis was begun. These
were assumed to be steady state levels, and rt-PA plasma
clearance was calculated by dividing them by the infusion rate.
Materials. High molecular weight (unfractionated) hepa-
rin (Liquemin) was purchased from Hoffman la Roche AG,
Grenzach-Wyhlen, Germany, Streptokinase (Streptase) from
Behringwerke, Marburg, Germany and rt-PA (Actilyse) from
Dr. Karl Thomae GmbH, Biberach, Germany. For laboratory
monitoring the following test kits were used: Clauss fibrinogen
assay kit from Boehringer Mannheim GmbH, Mannheim,
Germany and the assay kit for t-PA antigen (Actibind t-PA)
from Immuno GmbH, Heidelberg, Germany. The chromo-
genic peptide substrate H-D-Val-Leu-Lys-pNA (S-2251) was
purchased from KabiVitrum GmbH, Munich, Germany.
Statistics. Statistical comparisons were performed with the
use of the t test and Fisher exact test. Only p values , 0.05
were considered significant. All reported p values are two-
sided. Continuous variables are given as mean value 6 SD.
Results
Pharmacokinetic simulations and design of the new regi-
men. rt-PA plasma concentration-time profiles simulated for
the different regimens are shown in Figure 1. The regimen of
Neuhaus et al. (17,18) (our regimen D) resulted in an initial
peak at 4,600 ng/ml, a first steady state plateau of ;4,000 ng/ml
Figure 1. Predicted rt-PA plasma concentration profiles for
various dosage regimens based on pharmacokinetic simula-
tion. Circles 5 measured rt-PA plasma concentrations
(mean 6 SD) during the new 60-min regimen. ECSG 5
European Cooperative Study Group.
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during 30 min and a second steady state level of 1,700 ng/ml
between 60 and 90 min after the start of infusions. The
European Cooperative Study Group regimen of 70 mg over
1.5 h (regimen C) (15,16) produced a lower initial peak of
3,900 ng/ml, a first plateau of only 2,100 ng/ml and a second
plateau of 1,000 ng/ml. With the implementation of a single
rt-PA bolus injection of 20 mg immediately followed by a
constant infusion of additional 80 mg of rt-PA over 60 min
(regimen A), the simulation predicted an initial peak of
6,100 ng/ml and a single steady state plateau of 3,500 ng/ml for
a duration of 1 h. This latter regimen was selected for further
investigation. For practical reasons, we decided to dissolve the
lyophilized substance (100 mg of rt-PA) in 50 ml instead of
100 ml of the solvent. The resulting rt-PA solution was then
withdrawn into a 50-ml syringe designed for use in a perfusion
pump and 10 ml was injected as a bolus. The syringe then was
mounted onto a perfusion pump and the remaining 40 ml of
the rt-PA solution was infused at a constant speed of 40 ml/h.
Comparison phase of the trial. The comparison phase of
the trial was carried out from February 1988 through April
1989 at Hannover Medical School. Four consecutive groups of
20 consecutive patients were enrolled into the study (Table 1).
Thrombolysis was performed with one of the four predefined
regimens. Patency as assessed in this phase of the study yielded
TIMI grade 3 flow in 80% of patients in regimen A and 35%,
50% and 60% in regimens B, C and D, respectively. Total
patency (TIMI grade 2 and grade 3 flow combined) was 85% in
regimen A and 50%, 55% and 70% in regimens B, C, and D,
respectively (Fig. 2). Thrombolysis was accompanied by signif-
icant consumption of fibrinogen (Fg), plasminogen (PLG) and
alpha2-antiplasmin (AP) (Table 2). In this part of the trial the
overall rate of any hemorrhage was 28.8%, but only three
patients required transfusions. Included in the overall bleeding
rate are one patient with retroperitoneal hemorrhage treated
conservatively (regimen B) and one patient with pseudoaneu-
rysm that required operation (regimen D). All other bleeding
events occurred at sites of intravenous or intraarterial access.
No strokes were observed in this phase of the trial, but five
patients (6.3%) died (one patient each in groups A, B and D
and two patients in group C).
Confirmation phase of the trial. The confirmation phase of
the trial was carried out from June 1989 through November
1992 at Hannover Medical School in 161 patients, and it was
continued in 93 additional patients at the Franz Volhard Clinic
from July 1993 through May 1995, resulting in a total enroll-
ment of 254 patients (Table 3). The patency assessment in this
part of the trial yielded 81.1% TIMI grade 3 flow with a total
patency rate (TIMI grade 2 and grade 3 flow) of 87.0% (Fig. 2)
with TIMI grade 3 and total patency rates at an interim
analysis after enrollment of 161 patients of 79.5% and 88.1%,
respectively. These values were not significantly different from
the final results. Follow-up angiography was obtained at 19.6 6
5.4 days in 164 (79.6%) of those patients with TIMI grade 3
flow at initial angiography. In seven patients (4.3%) the
initially successfully reperfused coronary artery was found to
be reoccluded (2.5% at Hannover, 5.4% at Berlin). During the
hospital phase three patients died, resulting in an overall
in-hospital mortality rate of 1.2%.
During thrombolysis Fg levels decreased from 4.2 6
1.0 g/liter to 3.6 6 0.8 g/liter (p , 0.01). PLG and AP levels
decreased from 113 6 23% and 92 6 27% to 60 6 21% (p ,
Figure 2. Patency results of the comparative phase (regimens
A to D) and confirmation phase (regimen E [identical to A]
of the trial. A 5 100 mg of rt-PA/60 min (60-min alteplase
protocol); B 5 2.25 106 IU of streptokinase; C 5 70 mg of
rt-PA/90 min; D 5 100 mg of rt-PA/90 min (Neuhaus
regimen); E 5 100 mg of rt-PA/60 min (60-min alteplase
protocol). Open bars 5 TIMI grade 3 patency; solid bars 5
total patency (TIMI grades 2 and 3).
Table 1. Baseline Characteristics and Results of the
Comparative Study
Regimen
B C D A
Patients 20 20 20 20
Female/male ratio 2:18 4:16 3:17 6:14
Age (yr) 59 6 10 56 6 10 58 6 9 55 6 10
Weight (kg) 86 6 13 82 6 10 80 6 4 83 6 11
Height (cm) 173 6 8 172 6 8 171 6 9 176 6 6
Results
TIMI 0 and 1 10 (50%) 9 (45%) 6 (30%) 3 (15%)
TIMI 2 and 3 10 (50%) 11 (55%) 14 (70%) 17 (85%)
TIMI 2 3 (15%) 1 (5%) 2 (10%) 1 (5%)
TIMI 3 7 (35%) 10 (50%) 12 (60%) 16 (80%)
Data are presented as number (%) of patients or mean value 6 SD. TIMI 5
Thrombolysis in Myocardial Infarction flow grade.
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0.01) and 42 6 16% (p , 0.01) of the standard values. The
rt-PA steady state plasma concentrations as assessed in 12
randomly selected patients resulted in 3.45 6 1.47 ng/ml at
baseline, and 3,560 6 340, 3,550 6 218 and 19.5 6 5.5 ng/ml at
30, 60 and 120 min into thrombolysis were in good agreement
with the simulated values (Fig. 1). They yielded an rt-PA
plasma clearance of 377 6 28 ml/min.
Bleeding complications developed in 57 patients (22.4%);
the majority were located at the catheter access site. Transfu-
sions $1 U of packed red blood cells were required by nine
patients (3.5%). Among these patients are two patients who
needed surgery for pseudoaneurysms and 1 patient with retro-
peritoneal bleeding. Three patients had a stroke, two of which
were ischemic and one was confirmed by computed tomogra-
phy to be a small intracranial hemorrhage. That patient
nevertheless recovered almost completely.
Discussion
In patients with AMI, rapid restoration of unrestricted
infarct-related artery blood flow (TIMI grade 3 flow) has been
established as the prime mediator of an improved clinical
outcome (4–6,25). The goal of rapid and complete coronary
reperfusion can be addressed with either primary coronary
angioplasty or thrombolytic therapy. With direct angioplasty,
.90% of the occluded coronary arteries can be reperfused
within an average of 30 to 40 min. However, for logistic and
other reasons, pharmacologic therapy is more often selected.
However, a major problem has been that even the most
aggressive thrombolytic regimens do not achieve complete
restoration of coronary blood flow in .50% to 60% of patients
(5,8,10). This state of affairs suggests an obvious need for
further improved thrombolytic regimens.
Many new plasminogen activators are under active investi-
gation in the quest for faster and more complete thrombolysis.
Staphylokinase, DSPAalpha-1 and the TNK-mutant of t-PA are
examples (26–28). Efforts continue to explore preferred dosing
strategies with these new agents, as well as with established
fibrinolytic agents because the quantity and schedule of dose
delivery may substantially affect efficacy. Efforts for improve-
ment are particularly directed at rt-PA, a plasminogen activa-
tor that offers a linear dose-effect relation in a wide dose range
(29–31). For the initial large trials with this agent, doses of 80
or 100 mg were infused within 3 h by some groups (15,32,33),
whereas others (16,34) selected doses of 0.75 mg/kg or 70 mg
infused within 90 min. In the TIMI II pilot trial (35), the dose
of rt-PA was increased to 150 mg given over 6 h. However, this
dose caused an unacceptably high rate of intracranial hemor-
rhage (36). Combining both increased efficacy with an accept-
ably low hemorrhagic risk (17,18), the accelerated, front-
loaded rt-PA regimen of 100 mg over 90 min (Neuhaus
regimen) proved to be a substantial improvement. With TIMI
grade 3 flow of only 54% at 90 min, even this improved rt-PA
dose regimen warrants further improvement (5).
On the basis of findings from animal studies (30,37) indi-
cating that high peak rt-PA plasma concentrations of brief
duration are highly effective in lysing clots without provoking
bleeding, other innovative strategies (7,37–40) included single-
or double-bolus administration of 30 or 50 mg of rt-PA.
Though seemingly most promising, the administration of two
50-mg rt-PA boluses 30 min apart failed to demonstrate
superiority over the Neuhaus regimen in terms of efficacy or
bleeding hazards (13,14). We chose to utilize computer simu-
lation models of the plasma rt-PA levels to design a new dosing
regimen that might achieve several apparently important phar-
macokinetic goals. These goals included 1) a high rt-PA plasma
Table 2. Hemostatic Variables of the Comparative Study
Regimen
B C D A
Plasminogen (%)
Before 98 6 12 113 6 33 97 6 28 104 6 33
After 120 min 15 6 6 76 6 24 83 6 35 65 6 26
Alpha2-antiplasmin (%)
Before 102 6 25 91 6 27 92 6 28 94 6 24
After 120 min 13 6 9 41 6 27 37 6 25 38 6 29
Fibrinogen (g/liter)
Before 3.0 6 1.5 3.1 6 1.4 3.7 6 1.2 3.9 6 1.3
After 120 min 0.4% 6 0.5 3.1 6 1.6 3.4 6 1.3 3.2 6 1.6
Data are presented as mean value 6 SD.
Table 3. Baseline Characteristics and Results of the Dose
Confirmation Study
Patients 254
Female:male ratio 63:189
Age (yr) 59 6 8
Weight (kg) 76 6 12
Height (cm) 174 6 8
Results
TIMI 0 and 1 33 (13.0%)
TIMI 2 and 3 221 (87.0%)
TIMI 2 15 (5.9%)
TIMI 3 206 (81.1%)
Data are presented as mean value 6 SD or number (%) of patients. TIMI 5
Thrombolysis in Myocardial Infarction flow grade.
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concentration that is maintained over 60 min, 2) an initially
high peak rt-PA plasma level, and 3) maintenance below the
rt-PA threshold beyond which the “plasminogen steal” para-
doxically reduces the thrombolytic efficacy of the agent (41,42).
Because the Neuhaus regimen appears quite safe, we targeted
a high initial peak rt-PA plasma level followed by a plateau
level similar to the first plateau level of the Neuhaus regimen.
We also sought to achieve greater simplicity and ease of
administration than those of the current regimens. Current
regimens require either changing the infusion rate or the
administration of the second bolus precisely 30 min into
treatment. The 60-min protocol we subsequently selected for
testing consisted of a single 20-mg rt-PA bolus given up front
and an 80-mg constant infusion over the next 60 min. This
regimen appeared capable of achieving the stated goals.
Our 60-min alteplase regimen produced very encouraging
results. In a first comparative trial with 2.25 megaU of SK given
over 60 min, 70 mg of rt-PA given over 90 min and the
Neuhaus regimen, our alteplase regimen produced 80% TIMI
grade 3 patency compared with 35%, 50% and 60%, respec-
tively. The 85% total patency (TIMI grade 2 and 3) of our
regimen was also favorable compared with 50%, 55% and 70%
for the other treatments, respectively. Furthermore, there was
no apparent increase in bleeding hazard. For the nonrandom-
ized design of the study and the small number of patients
enrolled, the favorable patency rates of the 60-min alteplase
protocol, although consistent with our expectations, may have
resulted from chance. We therefore further tested the efficacy
and safety of this regimen further in an open, nonrandomized
trial in 254 consecutive patients. The TIMI grade 3 and total
patency rate assessments by independent investigators were
81.1% and 87.0% with an in-hospital mortality rate as low as
1.2%. Furthermore, only 3.5% of patients required blood
transfusions. The new regimen produced nadir PLG and AP
levels of 65 6 25% and 60 6 21% that were within the targeted
concentration range. Importantly, the ease of administration of
this dosing regimen resulted in excellent acceptance by physi-
cians and nurses in the emergency and intensive care environ-
ments.
Study limitations. The major limitation of our study is that
it was open label and nonrandomized. However, the principal
end point, TIMI grade 3 patency at 90 min, was established by
the interpretations of at least two experienced and indepen-
dent angiographers. Thus, the potential impact of investigator
enthusiasm was limited. The large number of patients studied
and the consistently high TIMI grade 3 patency rates over the
entire 5.5 years of patient enrollment make us confident in our
conclusion that our protocol has utility. Nevertheless, we are
aware that multicenter studies tend to yield lower patency rates
than those of single-center investigations. Our results should
be confirmed by a blinded, randomized comparison with an
alternative treatment such as reteplase or the t-PA regimen
used by the GUSTO I investigators.
Conclusions. In summary, we developed a new accelerated
front-loaded rt-PA dosage regimen for thrombolysis in AMI.
We designed our regimen on the basis of computer-assisted
pharmacokinetic simulations. This regimen consists of an
initial 20 mg i.v. bolus followed immediately by the continuous
infusion of an additional 80 mg over the next 60 min. In
addition to offering greatly improved handling properties in an
emergency setting, this new rt-PA dose regimen produced
TIMI grade 3 patency in 80% of patients both in a small
comparative phase of the trial and in a larger confirmation
phase in 254 consecutive patients. This patency advantage was
not achieved at the expense of increased bleeding hazards. We
conclude that this protocol warrants further study in a double-
blind, multicenter trial in a large cohort of patients with AMI.
We are grateful to Alan A. Ross, George Washington University, Washington
D.C. for help in writing the manuscript and to Kerstin Seidler for secretarial
assistance.
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